Nanoconjugation of PSMA-targeting ligands enhances perinuclear localization and improves efficacy of delivered alpha-particle emitters against tumor endothelial analogues

Molecular Cancer Therapeutics

Volumn 15, Issue 1, 2016, Pages 106-113

  Zhu, Charles ^a   Bandekar, Amey ^b   Sempkowski, Michelle ^a   Banerjee, Sangeeta Ray ^c   Pomper, Martin G ^c   Bruchertseifer, Frank ^d   Morgenstern, Alfred ^d   Sofou, Stavroula ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b The State University of New Jersey   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINIUM 225; GAMMA HISTONE H2AX; HISTONE H2AX; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; ACTINIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; H2AFX PROTEIN, HUMAN; HISTONE; LIGAND; LIPID; MEMBRANE ANTIGEN; NANOCONJUGATE; RADIOPHARMACEUTICAL AGENT;

ANTIGEN EXPRESSION; ARTICLE; CELL NUCLEUS; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONJUGATION; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SELECTIVITY; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INTERNALIZATION; ISOTOPE LABELING; LIPID VESICLE; NANOCONJUGATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RADIOACTIVITY; RADIOISOTOPE THERAPY; WESTERN BLOTTING; ALPHA RADIATION; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; ENDOTHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; INTRACELLULAR SPACE; MALE; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ACTINIUM; ALPHA PARTICLES; ANTIGENS, SURFACE; BIOLOGICAL TRANSPORT; CELL LINE; CELL SURVIVAL; ENDOTHELIAL CELLS; FLOW CYTOMETRY; GLUTAMATE CARBOXYPEPTIDASE II; HISTONES; HUMANS; INTRACELLULAR SPACE; LIGANDS; LIPIDS; MALE; MICROSCOPY, FLUORESCENCE; NANOCONJUGATES; RADIOPHARMACEUTICALS;

EID: 84958156913     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0207     Document Type: Article

References (25)

1. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
2. Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995;36:237-51.
3. Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, et al. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine 2010;5:783-802.
4. Kennel SJ, Mirzadeh S, Eckelman WC, Waldmann TA, Garmestani K, Yordanov AT, et al. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At. Radiat Res 2002;157:633-41.
5. Boswell CA, Brechbiel MW.Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you. J Nucl Med 2005;46:1946-7.
6. Dudley AC. Tumor endothelial cells. Cold Spring Harb Perspect Med 2012;2:a006536.
7. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
8. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57: 3629-34.
9. Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specificmembrane antigen (PSMA). Cancer Biol Ther 2008;7:974-82.
10. Pommé S, Marouli M, Suliman G, Dikmen H, Van Ammel R, Jobbágy V, et al. Measurement of the 225Ac half-life. Appl Radiat Isot 2012;70: 2608-14.
11. Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, et al. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl 2011;50:9167-70.
12. Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular a-particle therapy of cancer. J Nucl Med 2014;55:107-14.
13. McDevitt MR, Ma D, Simon J, Frank RK, Kiefer GE, Scheinberg DA. Design and synthesis of actinium-225 radioimmunopharmaceuticals. Appl Radiat Isot 2002;57:841-7.
14. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-100.
15. Liu T, Jabbes J, Nedrow-Byers JR, Wu LY, Bryan JN, Berkman CE. Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium. Int J Oncol 2011;38:1349-55.
16. Chen Y, Pullambhatla M, Banerjee SR, Byun Y, Stathis M, Rojas C, et al. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem 2012;23:2377-85.
17. Ballangrud AM, Yang W-H, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, et al. Response of LNCaP spheroids after treatment with an aparticle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001;61:2008-14.
18. Tung CJ, Liu CS, Wang JP, Chang SL. Calculations of cellular microdosimetry parameters for alpha particles and electrons. Appl Radiat Isot 2004;61:739-43.
19. Rosenkranz AA, Vaidyanathan G, Pozzi OR, Lunin VG, Zalutsky MR, Sobolev AS. Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to a-particle emitting 211At. Int J Radiat Oncol Biol Phys 2008;72:193-200.
20. Schülke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci 2003;100: 12590-5.
21. Baidoo KE, Yong K, Brechbiel MW.Molecular pathways: targeted a-particle radiation therapy. Clin Cancer Res 2013;19:530-7.
22. Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci 2010;107: 14541-6.
23. Vaziri B,Wu H, Dhawan AP, Du P, Howell RW, SNMMI MIRD Committee. MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations. J Nucl Med 2014;55:1557-64.
24. Elias DR, Poloukhtine A, Popik V, Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine 2013;9:194-201.
25. Jiang W, KimBetty YS, Rutka JT, ChanWarren CW. Nanoparticle-mediated cellular response is size-dependent. Nat Nano 2008;3:145-50.